Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Erin E. Congdon"'
Autor:
Yixiang Jiang, Yan Lin, Amber M. Tetlow, Ruimin Pan, Changyi Ji, Xiang-Peng Kong, Erin E. Congdon, Einar M. Sigurdsson
Publikováno v:
Molecular Neurodegeneration, Vol 19, Iss 1, Pp 1-24 (2024)
Abstract Synucleinopathies are a group of neurodegenerative diseases characterized by the accumulation of α-synuclein (α-syn) in the brain, leading to motor and neuropsychiatric symptoms. Currently, there are no known cures for synucleinopathies, a
Externí odkaz:
https://doaj.org/article/a84e6645814e4c4b8b53a044a5b7e94a
Autor:
Erin E. Congdon, Ruimin Pan, Yixiang Jiang, Leslie A. Sandusky-Beltran, Andie Dodge, Yan Lin, Mengyu Liu, Min-Hao Kuo, Xiang-Peng Kong, Einar M. Sigurdsson
Publikováno v:
EBioMedicine, Vol 84, Iss , Pp 104249- (2022)
Summary: Background: Eleven tau immunoglobulin G (IgG) antibodies have entered clinical trials to treat tauopathies, including Alzheimer's disease, but it is unclear which IgG subclass/subtype has the ideal efficacy and safety profile. Only two subty
Externí odkaz:
https://doaj.org/article/d4ff9d1847ab4f769c5682d1fe1e6d3b
Autor:
Erin E. Congdon, Jessica E. Chukwu, Dov B. Shamir, Jingjing Deng, Devyani Ujla, Hameetha B.R. Sait, Thomas A. Neubert, Xiang-Peng Kong, Einar M. Sigurdsson
Publikováno v:
EBioMedicine, Vol 42, Iss , Pp 157-173 (2019)
Background: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, th
Externí odkaz:
https://doaj.org/article/be5e77a5ea40444d949da97a0e989c9e
Autor:
Qian Wu, Yang Bai, Wei Li, Erin E. Congdon, Wenke Liu, Yan Lin, Changyi Ji, Wen-Biao Gan, Einar M. Sigurdsson
Publikováno v:
Neurobiology of Disease, Vol 147, Iss , Pp 105165- (2021)
Perturbed neuronal Ca2+ homeostasis is implicated in Alzheimer's disease, which has primarily been demonstrated in mice with amyloid-β deposits but to a lesser and more variable extent in tauopathy models.In this study, we injected AAV to express Ca
Externí odkaz:
https://doaj.org/article/e5c4ccb26c1843cf9df2959327faf020
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
We and others have shown in various in vivo, ex vivo and cell culture models that several tau antibodies interact with pathological tau within neurons. To further clarify this interaction in a dynamic human model, we differentiated SH-SY5Y cells with
Externí odkaz:
https://doaj.org/article/0f74233ab16b469c9209c49f60069447
Autor:
Yixiang Jiang, Yan Lin, Senthilkumar Krishnaswamy, Ruimin Pan, Qian Wu, Leslie A. Sandusky-Beltran, Mengyu Liu, Min-Hao Kuo, Xiang-Peng Kong, Erin E. Congdon, Einar M. Sigurdsson
Publikováno v:
Science Advances. 9
Intracellular deposition of α-synuclein and tau are hallmarks of synucleinopathies and tauopathies, respectively. Recently, several dye-based imaging probes with selectivity for tau aggregates have been developed, but suitable imaging biomarkers for
Autor:
Yixiang Jiang, Yan Lin, Senthilkumar Krishnaswamy, Qian Wu, Ruimin Pan, Mengyu Liu, Min‐Hao Kuo, Xiang‐Peng Kong, Erin E. Congdon, Einar M. Sigurdsson
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Erin E. Congdon
Publikováno v:
Frontiers in Neuroscience, Vol 12 (2018)
Alzheimer's disease (AD) is the most common form of dementia, with over 5. 4 million cases in the US alone (Alzheimer's Association, 2016). Clinically, AD is defined by the presence of plaques composed of Aβ and neurofibrillary pathology composed of
Externí odkaz:
https://doaj.org/article/fabd5d53595e48f28976697c4b2fd453
Autor:
Einar M. Sigurdsson, Erin E. Congdon
Publikováno v:
Nature Reviews Neurology. 14:399-415
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, resulting in cognitive deficits and eventually
Publikováno v:
mAbs. 11(3)
Targeting tau with immunotherapies is currently the most common approach taken in clinical trials of patients with Alzheimer’s disease. The most prominent pathological feature of tau is its hyperphosphorylation, which may cause the protein to aggre